GGrantIndex
← Leaderboards

Patricia J Giardina

Weill Medical College Of Cornell Univ

$4,084,595
Attributed
$4,084,595
Total exposure
10
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $446.2K · FY200511
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$2,955,434 · 8
CDC$1,129,161 · 2

By mechanism

U01$3,162,941 · 2
M01$698,743 · 7
U27$222,911 · 1

Top collaborators

No co-investigators on record.

Most similar at Weill Medical College Of Cornell Univ

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman Therapy EvaluationHuman SubjectThalassemiaClinical TrialsDeferoxamineDrug Screening /EvaluationIron MetabolismPatient /Disease RegistryChelation TherapyMedical ComplicationAntineoplasticsBlood TransfusionBone MetabolismMetabolism Disorder ChemotherapyImmunotherapyAntiinflammatory AgentsInterferonsMicroorganism Disease ChemotherapyHepatitis CCooperative StudyCombination TherapyIron DisorderOsteoporosis

Grant awards (33)

Prevention of Complications of Thalassemia$150,000
U01 · FY2011 · DD · contact PI
Prevention of Complications of Thalassemia$150,000
U01 · FY2010 · DD · contact PI
Prevention of Complications of Thalassemia$200,000
U01 · FY2009 · DD · contact PI
Thalassemia Clinical Research Network$105,341
U01 · FY2009 · HL · contact PI
Prevention of Complications of Thalassemia$200,000
U01 · FY2008 · DD · contact PI
Thalassemia Clinical Research Network$105,340
U01 · FY2008 · HL · contact PI
Prevention of Complications of Thalassemia$206,250
U01 · FY2007 · DD · contact PI
Thalassemia Clinical Research Network$105,338
U01 · FY2007 · HL · contact PI
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$3,102
M01 · FY2007 · RR · contact PI
PREVENTION OF THE COMPLICATIONS OF THALASSEMIA$222,911
U27 · FY2006 · DD · contact PI
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$81,024
M01 · FY2006 · RR · contact PI
Thalassemia Clinical Research Network$1
U01 · FY2006 · HL · contact PI
Thalassemia Clinical Research Network$215,874
U01 · FY2005 · HL
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$209,163
M01 · FY2005 · RR
THALASSEMIA CLINICAL RESEARCH NETWORK CROSS-SECTIONAL STUDY OF OSTEOPOROSIS$21,136
M01 · FY2005 · RR
PREVENTION OF THE COMPLICATIONS OF THALASSEMIA$0
U27 · FY2005 · DD
NEW YORK REGION THALASSEMIA CENTER$344,200
U01 · FY2004 · HL
PREVENTION OF THE COMPLICATIONS OF THALASSEMIA$0
U27 · FY2004 · DD
NEW YORK REGION THALASSEMIA CENTER$360,600
U01 · FY2003 · HL
PREVENTION OF THE COMPLICATIONS OF THALASSEMIA$0
U27 · FY2003 · DD
NEW YORK REGION THALASSEMIA CENTER$350,097
U01 · FY2002 · HL
DMHP(DEFERIPRONE)--AN ORAL IRON CHELATION AGENT FOR THALASSEMIA$0
M01 · FY2002 · RR
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$0
M01 · FY2002 · RR
A COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKIN'S DISEASE$0
M01 · FY2002 · RR
PREVENTION OF THE COMPLICATIONS OF THALASSEMIA$0
U27 · FY2002 · DD
NEW YORK REGION THALASSEMIA CENTER$339,900
U01 · FY2001 · HL
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$0
M01 · FY2001 · RR
A COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKIN'S DISEASE$0
M01 · FY2001 · RR
DMHP(DEFERIPRONE)--AN ORAL IRON CHELATION AGENT FOR THALASSEMIA$0
M01 · FY2001 · RR
NEW YORK REGION THALASSEMIA CENTER$330,000
U01 · FY2000 · HL
A COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKIN'S DISEASE$128,106
M01 · FY2000 · RR
DESFERRIOXAMINE THERAPY IN IRON OVERLOAD$128,106
M01 · FY2000 · RR
DMHP(DEFERIPRONE)--AN ORAL IRON CHELATION AGENT FOR THALASSEMIA$128,106
M01 · FY2000 · RR